|
Press Releases |
|
|
|
Thursday, August 24, 2023 |
|
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug |
more info >> |
|
Monday, July 31, 2023 |
|
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management |
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices. more info >> |
|
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management |
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices. more info >> |
|
Thursday, June 29, 2023 |
|
China Medical System Included in the First 'Sustainability Yearbook (China)' of S&P Global |
more info >> |
|
Monday, June 12, 2023 |
|
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China |
more info >> |
|
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China |
more info >> |
|
Tuesday, May 30, 2023 |
|
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China |
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. more info >> |
|
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China |
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. more info >> |
|
Monday, December 19, 2022 |
|
Gelonghui Reports CMS' Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets |
Gelonghui released a Press Release on "China Medical System Holdings Limited's innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets ('the Product') has obtained positive results for its Phase III clinical trial in China." more info >> |
|
Friday, November 18, 2022 |
|
China Medical System (867.HK) S&P Global CSA Score Achieved Significant Improvement, Leading the Industry Globally |
Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited ("CMS" or the "Group"). CMS achieved a significant improvement with a score of 53 in 2022 from 36 in 2021, surpassing 92% of the global peers and being significantly ahead of the industry average. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 19:02: JST
|
|
|
海通恒信业绩出炉:切实服务实体经济发展 经营质效稳步提升
Mar 29, 2024 18:56 HKT/SGT
|
|
|
海通恒信業績出爐:切實服務實體經濟發展 經營質效穩步提升
Mar 29, 2024 18:52 HKT/SGT
|
|
|
和泓服务:深耕西南区域,业绩稳健增长
Mar 29, 2024 18:43 HKT/SGT
|
|
|
和泓服務:深耕西南區域,業績穩健增長
Mar 29, 2024 18:31 HKT/SGT
|
|
|
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 29, 2024 18:15 HKT/SGT
|
|
|
锅圈:持续扩大业务规模 盈利能力持续增强
Mar 29, 2024 18:10 HKT/SGT
|
|
|
鍋圈:持續擴大業務規模 盈利能力持續增強
Mar 29, 2024 18:07 HKT/SGT
|
|
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 18:02 HKT/SGT
|
|
|
Legend Holdings Realized Revenue of RMB436 billion in 2023
Mar 29, 2024 17:55: JST
|
|
|
直面企业发展转型挑战 联想控股如何发展新质生产力
Mar 29, 2024 17:14 HKT/SGT
|
|
|
直面企業發展轉型挑戰 聯想控股如何發展新質生產力
Mar 29, 2024 17:10 HKT/SGT
|
|
|
联想控股2023年收入4360亿元
Mar 29, 2024 17:05 HKT/SGT
|
|
|
聯想控股2023年收入4360億元
Mar 29, 2024 17:01 HKT/SGT
|
|
|
Legend Holdings Realized Revenue of RMB436 billion in 2023
Mar 29, 2024 16:55 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|